Compare Petróleo Brasileiro SA (PBR) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Petróleo Brasileiro SA vs Twist Bioscience Corp — how do they compare? Petróleo Brasileiro SA trades at $25.39 (market cap $151.94B), while Twist Bioscience Corp trades at $162.26 (market cap $10.08B). The key difference: Petróleo Brasileiro SA is far larger — about 15.1× Twist Bioscience Corp's market cap, and Petróleo Brasileiro SA pays a 6.79% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Petróleo Brasileiro SA for 25 Days and Twist Bioscience Corp for 27 Days on average.
| PBR | TWST | |
|---|---|---|
Market Cap | $151.94B | $10.08B |
Volume | 30,240,092 | 4,229,037 |
Sector | Energy | Health |
52-Week High | $24.69 | $205.00 |
52-Week Low | $11.54 | $25.45 |
Typical Hold Time | 25 Days | 27 Days |
Enterprise Value | $212.36B | $10.01B |
Dividend Yield | 6.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Petrobras (PBR) is trading at $25.16, up 4.88% with strong bullish momentum. The stock shows robust fundamentals with a P/E of 6.24, net margin of 24.52%, and positive earnings surprises in recent quarters. Recent news highlights new oil discoveries and production growth initiatives, while technical indicators show overbought conditions with RSI above 80.
PBR offers attractive valuation metrics and strong profitability, but faces risks from political interference and commodity price volatility. Analyst consensus leans bullish with 50% buy ratings, though the current price exceeds the $22.33 consensus target. The company's expansion projects and LNG deals provide long-term growth catalysts.
Twist Bioscience (TWST) trades at $162.43, up 4.36% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical signal with RSI at 29.02 indicating potential oversold conditions. Fundamentally, revenue growth continues (2025: $377M, 2026: $432M projected) but profitability remains elusive with negative margins. Recent partnership with Eli Lilly's TuneLab platform highlights strategic positioning in AI-driven drug discovery.
While analyst consensus favors Buy (73%), the stock trades above the $145.20 target, suggesting limited near-term upside. Key risks include persistent cash burn (-$44M net CF in 2025) and high valuation multiples (P/S: 21.5). The AI biotech partnership provides growth catalyst potential, but profitability timeline remains uncertain for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
